annual EBITDA:
-$141.71M-$87.60M(-161.89%)Summary
- As of today (September 14, 2025), MLTX annual EBITDA is -$141.71 million, with the most recent change of -$87.60 million (-161.89%) on December 31, 2024.
- During the last 3 years, MLTX annual EBITDA has fallen by -$88.13 million (-164.52%).
- MLTX annual EBITDA is now -133837.90% below its all-time high of -$105.80 thousand, reached on December 1, 2020.
Performance
MLTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$59.96M-$12.85M(-27.28%)Summary
- As of today (September 14, 2025), MLTX quarterly EBITDA is -$59.96 million, with the most recent change of -$12.85 million (-27.28%) on June 30, 2025.
- Over the past year, MLTX quarterly EBITDA has dropped by -$29.41 million (-96.25%).
Performance
MLTX quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$198.42M-$29.41M(-17.40%)Summary
- As of today (September 14, 2025), MLTX TTM EBITDA is -$198.42 million, with the most recent change of -$29.41 million (-17.40%) on June 30, 2025.
- Over the past year, MLTX TTM EBITDA has dropped by -$120.07 million (-153.26%).
Performance
MLTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
MLTX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -161.9% | -96.3% | -153.3% |
| 3 y3 years | -164.5% | -239.7% | -266.6% |
| 5 y5 years | -10000.0% | -100.0% | -100.0% |
MLTX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -164.5% | at low | -363.8% | at low | -266.7% | at low |
| 5 y | 5-year | <-9999.0% | at low | <-9999.0% | at low | <-9999.0% | at low |
| alltime | all time | <-9999.0% | at low | <-9999.0% | at low | <-9999.0% | at low |
MLTX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$59.96M(+27.3%) | -$198.42M(+17.4%) |
| Mar 2025 | - | -$47.11M(-2.4%) | -$169.02M(+19.3%) |
| Dec 2024 | -$141.71M(+161.9%) | -$48.28M(+12.1%) | -$141.71M(+30.7%) |
| Sep 2024 | - | -$43.08M(+41.0%) | -$108.45M(+38.4%) |
| Jun 2024 | - | -$30.55M(+54.3%) | -$78.35M(+28.5%) |
| Mar 2024 | - | -$19.80M(+31.8%) | -$60.98M(+12.7%) |
| Dec 2023 | -$54.11M(-16.8%) | -$15.03M(+15.8%) | -$54.11M(-3.0%) |
| Sep 2023 | - | -$12.97M(-1.6%) | -$55.78M(-3.1%) |
| Jun 2023 | - | -$13.18M(+2.0%) | -$57.57M(-7.2%) |
| Mar 2023 | - | -$12.93M(-22.6%) | -$62.04M(-4.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2022 | -$65.05M(+21.4%) | -$16.69M(+13.0%) | -$65.05M(+3.9%) |
| Sep 2022 | - | -$14.77M(-16.3%) | -$62.63M(+15.7%) |
| Jun 2022 | - | -$17.65M(+10.7%) | -$54.13M(-21.7%) |
| Mar 2022 | - | -$15.94M(+11.7%) | -$69.16M(+29.7%) |
| Dec 2021 | -$53.57M(>+9900.0%) | -$14.27M(+127.8%) | -$53.32M(+36.2%) |
| Sep 2021 | - | -$6.26M(-80.8%) | -$39.14M(+19.1%) |
| Jun 2021 | - | -$32.68M(>+9900.0%) | -$32.88M(>+9900.0%) |
| Mar 2021 | - | -$94.10K(-6.6%) | -$194.90K(+93.4%) |
| Dec 2020 | -$105.80K | -$100.80K(<-9900.0%) | -$100.80K(<-9900.0%) |
| Sep 2020 | - | $0.00 | $0.00 |
FAQ
- What is MoonLake Immunotherapeutics annual EBITDA?
- What is the all time high annual EBITDA for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics annual EBITDA year-on-year change?
- What is MoonLake Immunotherapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics quarterly EBITDA year-on-year change?
- What is MoonLake Immunotherapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics TTM EBITDA year-on-year change?
What is MoonLake Immunotherapeutics annual EBITDA?
The current annual EBITDA of MLTX is -$141.71M
What is the all time high annual EBITDA for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high annual EBITDA is -$105.80K
What is MoonLake Immunotherapeutics annual EBITDA year-on-year change?
Over the past year, MLTX annual EBITDA has changed by -$87.60M (-161.89%)
What is MoonLake Immunotherapeutics quarterly EBITDA?
The current quarterly EBITDA of MLTX is -$59.96M
What is the all time high quarterly EBITDA for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high quarterly EBITDA is $0.00
What is MoonLake Immunotherapeutics quarterly EBITDA year-on-year change?
Over the past year, MLTX quarterly EBITDA has changed by -$29.41M (-96.25%)
What is MoonLake Immunotherapeutics TTM EBITDA?
The current TTM EBITDA of MLTX is -$198.42M
What is the all time high TTM EBITDA for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high TTM EBITDA is $0.00
What is MoonLake Immunotherapeutics TTM EBITDA year-on-year change?
Over the past year, MLTX TTM EBITDA has changed by -$120.07M (-153.26%)